Lipum AB (publ)

Stockholm Stock Exchange:LIPUM.ST

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

Sweden

Market Cap

USD 32.59 M

Share Price

USD 1.54

Avg Daily Volume

4,747

Change (1 day)

2.77%

Change (1 year)

85.67%

Change (YTD)

41.76%

Lipum AB (publ) Revenue for the year ending December 31, 2024: USD 0.00

Lipum AB (publ) Revenue is USD 0.00 for the year ending December 31, 2024, a -100.00% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Lipum AB (publ) Revenue for the year ending December 31, 2023 was USD 5.23 K.
Lipum AB (publ) Revenue for the year ending December 31, 2022 was USD 0.00.
Lipum AB (publ) Revenue for the year ending December 31, 2021 was USD 0.00, a -100.00% change year over year.
Lipum AB (publ) Revenue for the year ending December 31, 2020 was USD 1.79 K, a -56.83% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

Stockholm Stock Exchange: LIPUM.ST

Lipum AB (publ)

CEO	Mr. Ola Sandborgh
IPO Date	April 22, 2021
Location	Sweden
Headquarters	Tvistevägen 48C
Employees	5
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of pediatric rheumatism and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116. The company was founded in 2010 and is headquartered in Umeå, Sweden.